Will Chemoradiation-based Bladder-sparing Therapy Become a Standard of Care for Muscle-invasive Bladder Cancer?

Overview

Journal Transl Androl Urol

Date 2020 Jul 18

PMID 32676378

Authors

Fumitaka Koga

Affiliations

Soon will be listed here.

References

Rodel C, Grabenbauer G, Kuhn R, Papadopoulos T, Dunst J, Meyer M . Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002; 20(14):3061-71. DOI: 10.1200/JCO.2002.11.027. View

Theelen W, Peulen H, Lalezari F, van der Noort V, de Vries J, Aerts J . Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019; 5(9):1276-1282. PMC: 6624814. DOI: 10.1001/jamaoncol.2019.1478. View

Huddart R, Hall E, Lewis R, Birtle A . Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed. BJU Int. 2010; 106(6):753-5. DOI: 10.1111/j.1464-410X.2010.09537.x. View

Efstathiou J, Spiegel D, Shipley W, Heney N, Kaufman D, Niemierko A . Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2011; 61(4):705-11. DOI: 10.1016/j.eururo.2011.11.010. View

Ngwa W, Irabor O, Schoenfeld J, Hesser J, Demaria S, Formenti S . Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018; 18(5):313-322. PMC: 5912991. DOI: 10.1038/nrc.2018.6. View

Chang S, Bochner B, Chou R, Dreicer R, Kamat A, Lerner S . Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol. 2017; 198(3):552-559. PMC: 5626446. DOI: 10.1016/j.juro.2017.04.086. View

Huddart R, Hall E, Lewis R, Porta N, Crundwell M, Jenkins P . Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. Eur Urol. 2019; 77(2):260-268. PMC: 6983941. DOI: 10.1016/j.eururo.2019.11.001. View

STONE H, Peters L, Milas L . Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst. 1979; 63(5):1229-35. View

Kulkarni G, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P . Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. J Clin Oncol. 2017; 35(20):2299-2305. DOI: 10.1200/JCO.2016.69.2327. View

10.

Witjes J, Lebret T, Comperat E, Cowan N, De Santis M, Bruins H . Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 2016; 71(3):462-475. DOI: 10.1016/j.eururo.2016.06.020. View

11.

James N, Hussain S, Hall E, Jenkins P, Tremlett J, Rawlings C . Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012; 366(16):1477-88. DOI: 10.1056/NEJMoa1106106. View